---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-009805"
form_type: "8-K"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2026-02-19T23:59:59+00:00"
generated_at: "2026-05-16T01:41:25.352069+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Vanda Pharmaceuticals sets 2025 bonuses, 2026 salaries, and grants RSUs/PSUs to executives

## Summary
- CEO Polymeropoulos gets $834,326 2025 bonus; 2026 base $994,625, target bonus 80%.
- Other NEOs 2025 bonuses $272k-$282k; 2026 base $576,735-$596,990, target 45%.
- RSUs: 525,000 to CEO, 125,000 to each of four other NEOs; vest in 4 equal annual installments.
- PSUs: target 175,000 (CEO), 40,000 (others); payout 0%-150% based on relative TSR vs Nasdaq Biotech Index over 3 years.
- Compensation Committee used Willis Towers Watson peer analysis in determining compensation.

## SEC filing metadata
- accession: 0001628280-26-009805
- form_type: 8-K
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2026-02-19T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000162828026009805/0001628280-26-009805-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000162828026009805/vnda-20260218.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-009805
- JSON: https://secwatch.observer/filing/0001628280-26-009805.json
- Plain text: https://secwatch.observer/filing/0001628280-26-009805.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.